Polymeric micellar paclitaxel plus cisplatin combined with tislelizumab as the first-line treatment of advanced unresectable esophageal squamous cell carcinoma: A phase II study.

被引：0
|
作者：
Cao, Guochun
Li, Xiaoyou
Liu, Delin
Zhu, Jinghua
机构：
[1] Nanjing Med Univ, Affiliated Canc Hosp, Dept Clin Oncol, Jiangsu Canc Hosp,Jiangsu Inst Canc Res, Nanjing, Peoples R China
[2] Jiangsu Canc Hosp, Dept Med Oncol, Nanjing, Peoples R China
[3] China Jinagsu Prov Inst Canc Res, Nanjing, Jiangsu, Peoples R China
[4] Jiangsu Canc Hosp, Nanjing, Jiangsu, Peoples R China
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2024年 / 42卷 / 16期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
e16022
引用
收藏
页数：1
相关论文
共 50 条
  • [41] A phase II study of paclitaxel and carboplatin plus PD-1 inhibitors combined with anlotinib as first-line treatment for advanced esophageal cancer.
    Xu, Mingfang
    Pu, Yu
    Jiang, Yuzhu
    Liu, Hong
    Feng, Yan
    Qian, Chengyuan
    Dai, Nan
    Wang, Dong
    Li, Mengxia
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 : 395 - 395
  • [42] Tislelizumab Plus Chemotherapy Versus Placebo Plus Chemotherapy as First-Line Treatment for Chinese Patients with Advanced Esophageal Squamous Cell Carcinoma: A Cost-Effectiveness Analysis
    Shijie Lu
    Yake Lou
    Yi Rong
    Zirui Huang
    Xiaodan Lin
    Junying Chen
    Kongjia Luo
    Clinical Drug Investigation, 2023, 43 : 643 - 652
  • [43] SHR-1701 plus chemotherapy as first-line treatment for unresectable locally advanced, recurrent or metastatic esophageal squamous cell carcinoma (ESCC).
    Wang, Yi
    Liu, Hong
    Wang, Qingwei
    Qiao, Naian
    Wang, Jianbo
    Tan, Bingxu
    Cheng, Bo
    Chu, Yunxia
    Li, Huajun
    Cheng, Yufeng
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 : 363 - 363
  • [44] Conversion chemoradiotherapy combined with nab-paclitaxel plus cisplatin in patients with locally advanced borderline-resectable or unresectable esophageal squamous cell carcinoma: a phase i/ii prospective cohort study
    Yu, Nuo
    Chen, Xiankai
    Li, Jiao
    Kang, Xiaozheng
    Wang, Zhen
    Zhang, Ruixiang
    Qin, Jianjun
    Li, Yong
    Zheng, Qingfeng
    Feng, Guojie
    Deng, Lei
    Zhang, Tao
    Wang, Wenqing
    Liu, Wenyang
    Wang, Jianyang
    Feng, Qinfu
    Lv, Jima
    Zhou, Zongmei
    Xiao, Zefen
    Bi, Nan
    Li, Yin
    Wang, Xin
    STRAHLENTHERAPIE UND ONKOLOGIE, 2024, 200 (12) : 1038 - 1046
  • [45] Paclitaxel, cisplatin, and cyclophosphamide (PCC) first-line chemotherapy for advanced ovarian carcinoma:: Long-term results of a phase II study.
    García-Velasco, A
    Hernando, S
    Mendiola, C
    Castellano, D
    Sánchez-Muñoz, A
    Del Val, O
    Manso, L
    Quintela, M
    Cortés-Funes, H
    JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (14) : 482S - 482S
  • [46] A Phase II, Randomized Trial of Trilaciclib Plus Chemotherapy and Tislelizumab as First-Line Treatment for Advanced SqNSCLC
    Wang, Y.
    Shi, H.
    JOURNAL OF THORACIC ONCOLOGY, 2024, 19 (10) : S396 - S396
  • [47] Nivolumab combination therapy as first-line treatments for unresectable, advanced or metastatic esophageal squamous cell carcinoma
    Rogers, Jane E.
    Yamashita, Kohei
    Sewastjanow-Silva, Matheus
    Rosa Vicentini, Ernesto
    Waters, Rebecca
    Ajani, Jaffer A.
    EXPERT REVIEW OF ANTICANCER THERAPY, 2023, 23 (06) : 565 - 571
  • [48] Encouraging efficacy of sintilimab combined with nanoparticle albumin-bound paclitaxel and platinum as the first-line treatment for metastatic esophageal squamous cell carcinoma: A retrospective study.
    Wang, Chao-Jie
    Feng, Jiang-Shan
    Zhao, Wei-Feng
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16) : E16013 - E16013
  • [49] A randomized, phase 2 study of cetuximab plus cisplatin with or without paclitaxel for the first-line treatment of patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck
    Bossi, P.
    Miceli, R.
    Locati, L. D.
    Ferrari, D.
    Vecchio, S.
    Moretti, G.
    Denaro, N.
    Caponigro, F.
    Airoldi, M.
    Moro, C.
    Vaccher, E.
    Sponghini, A.
    Caldara, A.
    Rinaldi, G.
    Ferrau, F.
    Nole, F.
    Lo Vullo, S.
    Tettamanzi, F.
    Hollander, L.
    Licitra, L.
    ANNALS OF ONCOLOGY, 2017, 28 (11) : 2820 - 2826
  • [50] PD-1 inhibitors combined with paclitaxel and cisplatin in first-line treatment of esophageal squamous cell carcinoma (ESCC): a network meta-analysis
    Zhao, Jia
    Zhang, Simeng
    Guo, Xiaoyu
    Li, Ce
    Yang, Bowen
    Qu, Xiujuan
    Wang, Shuo
    BMC CANCER, 2023, 23 (01)
12345